Status and phase
Conditions
Treatments
About
The purpose of this study is to evaluate the efficacy and safety of CertiroBell® tablet compared with mycophenolate mofetil in primary living donor liver transplant recipients.
Full description
This study is multi-center, open-label, randomized controlled phase 4 study to evaluate the efficacy and safety of certirobell® tablet compared with mycophenolate mofetil in primary living donor liver transplant recipients.
On the first visit the patients scheduled to be operated liver transplant in 35 days will be conducted screening. Patients who meet the criteria of this clinical trial will be randomized to CertiroBell or mycophenolate mofetil on the second visit. Each group will take CertiroBell or mycophenolate mofetil and will conduct scheduled tests with 5 additional visits.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
* Inclusion Criteria:
[Time of screening]
[Time of randomization] - Patients who have transplanted liver within 4 weeks(25 days to 35 days)
* Exclusion Criteria
[Time of screening]
[Time of randomization]
Patients with acute rejection who have been clinically treated after liver transplantation.
Patients with complication related to the hepatic artery such as hepatic artery thrombosis at the time of randomization.
At screening
Patients taking HCV(hepatitis C virus) Therapeutic Drugs
Patients who had plasmapheresis within 1 week.
Patents who had a record of taking mTOR inhibitor before.
In investigator's judgement
Primary purpose
Allocation
Interventional model
Masking
150 participants in 2 patient groups
Loading...
Central trial contact
Soon Il Kim, M.D., Ph.D.; Soo J Myung
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal